Clinical Trial: A multicentre, randomised, blind, placebo-controlled phase III trial evaluating the effectiveness, safety and immune response of the recombinant respiratory syncytial virus vaccine (CHO cells) in people aged 60 and over (China)

China, Aug. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A multicentre, randomised, blind, placebo-controlled phase III trial evaluating the effectiveness, safety and immune response of the recombinant respiratory syncytial virus vaccine (CHO cells) in people aged 60 and over'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130214

Registration Time: 2026/08/17

Type: Interventional study

Primary Sponsor: Hebei Center for Disease Control and Prevention

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338280

Published by HT Digital Content Services with permission from Health Daily Digest....